ClinicalTrials.gg
CompletedNCT02094053Updated Aug 22, 2017

A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

A Phase 2 interventional study of E2020-Donepezil hydrochloride and E2020-Donepezil hydrochloride in Down Syndrome, sponsored by Eisai Co., Ltd.. Completed at 10 sites in Japan. Open to participants aged 15 Years to 39 Years. Per ClinicalTrials.gov, last updated 2017-08-22.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2013, registered Mar 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
15 Years to 39 Years
Sex
All
01

Study summary

The purpose of this double-blind, placebo-controlled, comparative study and open-label extension study is to confirm the efficacy and safety of E2020 in subjects with Down syndrome having regression symptoms and disabled activities of daily living.

Read the detailed description

This is a multicenter, randomized, double-blind, multiple-dose (two doses), placebo-controlled, parallel-group comparative study followed by an open-label extension study of E2020 in subjects with Down syndrome having regression and disabled ADL. A total of 60 subjects will be randomized to one of three dosing groups (at 1:1:1) to receive 3 mg of E2020, 5 mg of E2020, or placebo for 24 weeks based on their total scores of Body Functionality Checklist, sex, and study site as the allocation factors. This study consists of Pre-randomization Phase (4 weeks), Double-blind Phase (28 weeks), and Extension Phase (24 weeks). The Double-blind Phase includes a 24-week treatment period plus a 4-week transition period.

02

Conditions studied

  • Down Syndrome

Browse trials for

Keywords

  • Down syndrome
  • regression symptoms
  • disabled activities of daily living
03

In context

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

This study's enrollment of 36 is close to the median of 38 across 287 interventional studies indexed under Down Syndrome.

Browse Down Syndrome studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At enrollment in Pre-randomization Phase

  1. With definitive diagnosis of Down syndrome
  2. Have greater than or equal to 3 of the following 4 symptoms among 9 items according to the diagnostic criteria issued by the Intractable Diseases Treatment Research Program 2010 (Research paper on Intractable Diseases Treatment Research Program; Survey on Sudden Regression (21 trisomy) and Preparation of Diagnostic Criteria.) Motor retardation, mutism, social withdrawal (homeboundness), sleep disorder
  3. Insufficiently improved with environmental adjustment and psychotherapies including counseling for greater than or equal to 8 weeks before enrollment
  4. Have a suspected diagnosis with neuropsychiatric disorder without sufficient effect on a disease even after medical treatment for greater than or equal to 8 weeks before enrollment.
  5. A total score of Body Functionality Checklist (51 items) is lesser than or equal to 210 at enrollment
  6. Aged 15 to 39 years inclusive
  7. Males and females
  8. Must have a family member or a caregiver who will provide written and will be able to spend 3 days a week with the subject (at least 4 hours per day) and will be able to support the subject during the study by providing necessary study information to the subject, assisting treatment compliance, and accompanying the subject to all scheduled visits, supporting study-related tests for the efficacy and safety assessments throughout the study period
  9. Males and females of must practice highly effective
  10. Able to comply with scheduled study visits according to the investigator's instruction
  11. Able to visit for scheduled assessments (except for walking difficulty due to development of regression)
  12. Submitted written informed consent for study entry (to obtain from subjects as much as possible; mandatory from their legal guardian)

Exclusion criteria

Exclusion Criteria

At enrollment in Pre-randomization Phase

  1. Suspected to have progressive neuropsychiatric disease (e.g., neurodegenerative disorder and progressive tumor) evidenced by MRI or CT within 1 year before the Pre-randomization Phase (if not tested within 1 year before the Pre-randomization Phase, reconfirm during the Pre-randomization Phase).
  2. Have a history of significant neurological disorders such as stroke, brain tumor, encephalitis, meningitis, normal pressure hydrocephalus, brain trauma accompanying unconsciousness, and experience of brain surgery causing unsolved deficiency
  3. Previously diagnosed with autism
  4. With evidence of atlantoaxial subluxation, or underwent surgical operation for atlantoaxial subluxation within 2 years
  5. Have seizure symptoms within 2 years or used antiepileptic drug within 1 year before enrollment of Pre-randomization Phase.
  6. With severe hearing or visual impairment which may affect regression
  7. Have a complication of cardiac disease (angina pectoris, congestive heart failure, bundle branch block, arrythmia) or peripheral vascular disease with unstable condition in 3 months before enrollment of Pre-randomization Phase
  8. Have a complication of active and unstable diseases in the gastrointestinal, hepatic, renal, respiratory, or cardiovascular system
  9. Have a history of clinically significant gastrointestinal ulcer, bronchial asthma, or obstructive pulmonary disease
  10. Have a complication of disease affecting absorption, distribution, and metabolism of study drug (e.g., inflammatory colon disease, gastric ulcer, duodenal ulcer, hepatic disorder, serious lactose intolerance)
  11. With a present or past history of malignant tumor within 5 years before (except for basal cell carcinoma, squamous cell carcinoma)
  12. With a complication or history of drug or alcohol dependency within recent 10 years
  13. Have a known to ingredient(s) of donepezil hydrochloride or peperidine derivatives
  14. Not meet the criteria of prohibited and restricted concomitant medications, or anticipated to deviate from the above criteria of prohibited and restricted concomitant medications/therapies during the study
  15. Pregnant or lactating women
  16. Have participated in another clinical study and received the study drug within 12 weeks before the enrollment of this study
  17. Have used donepezil hydrochloride or have participated in a clinical study of E2020 and received E2020 in the past
  18. With a history of a treatment for Alzheimer's type dementia
  19. With severe extrapyramidal disorder

    At enrollment in the Double-blind Phase

  20. Suspected to have a complication of severe disease considering from the laboratory parameters at enrollment in the Pre-randomization Phase (visit 1) and the safety is not protected in the opinion of the principal investigator or subinvestigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    E2020 3 mg

    3 mg of E2020 (oral) once daily, for 24 weeks

    Drug: E2020-Donepezil hydrochloride

  • Experimental
    E2020 5 mg

    5 mg of E2020 (oral) once daily, for 24 weeks

    Drug: E2020-Donepezil hydrochloride

  • Placebo comparator
    Placebo

    placebo (oral) once daily, for 24 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in total scores from baseline using Body Functionality Checklist (psychosomatic function questionnaire) in subjects with Down syndrome having regression symptoms and disabled activities of daily living (ADL), relative to placebo.

    For the changes in a total score of Body Functionality Checklist (51 items) from Week 0 of the treatment period, Kruskal-Wallis test will be performed in the 3 mg group, the 5 mg group and placebo group to represent statistical significance. Summary statistics of the total score of Body Functionality Checklist (51 items) at each evaluation time and changes from before study drug administration in the treatment period will be calculated by dose group.

    Time frame: Baseline to Week 12 and Week 24

Secondary outcomes

  1. Safety of E2020 and placebo in subjects with Down syndrome having regression and disabled ADL.

    The safety will be measured by frequencies of treatment-emergent adverse events (TEAEs) in the treatment period, statistics of laboratory parameters, blood pressure, and pulse rate at each evaluation time and changes from before study drug administration, and 12-lead ECG assessment, frequency distribution (yes/no) at each evaluation time will be collected and the percent (%) will be calculated by dose group.

    Time frame: Up to Week 28

  2. Pharmacokinetics (PK) of E2020 and placebo in subjects with Down syndrome having regression and disabled ADL

    Population PK analysis will be performed to build PK models to explain plasma donepezil hydrochloride concentration data. In addition, the models may be used to explore relationship of PK data with demographics, efficacy, and AEs.

    Time frame: Up to Week 28

07

Study locations

10 sites
  • Fukuoka-shi, Fukuoka, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Takatsuki-shi, Kyoto, Japan
  • Matsumoto-shi, Nagano, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Izumi-shi, Osaka, Japan
  • Saitama-shi, Saitama, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Sep 2016, 36 months.

Of 21 phase 2 interventional studies under Down Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 61. This study's 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2014
First posted
Mar 21, 2014
StartActual
Sep 12, 2013
Primary completionActual
Sep 16, 2016
CompletionActual
Apr 21, 2017
Last update
Aug 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02094053
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 21, 2014
Start date
Sep 12, 2013
Primary completion
Sep 16, 2016
Completion
Apr 21, 2017
Last update
Aug 22, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion